Ulipristal acetate interferes with actin remodeling induced by 17β-estradiol and progesterone in human endometrial stromal cells by Shortrede, JORGE EDUARDO et al.
ORIGINAL RESEARCH
published: 27 June 2018
doi: 10.3389/fendo.2018.00350
Frontiers in Endocrinology | www.frontiersin.org 1 June 2018 | Volume 9 | Article 350
Edited by:
Michael Schumacher,
Institut National de la Santé et de la
Recherche Médicale (INSERM),
France
Reviewed by:
Maristela Oliveira Poletini,
Universidade Federal de Minas Gerais,
Brazil
Guillermo Romero,
University of Pittsburgh, United States
*Correspondence:
Tommaso Simoncini
tommaso.simoncini@med.unipi.it
†These authors have contributed
equally to this work and should be
considered as first co-authors.
Specialty section:
This article was submitted to
Cellular Endocrinology,
a section of the journal
Frontiers in Endocrinology
Received: 05 March 2018
Accepted: 11 June 2018
Published: 27 June 2018
Citation:
Shortrede JE, Montt-Guevara MM,
Pennacchio G, Finiguerra M,
Giannini A, Genazzani AD and
Simoncini T (2018) Ulipristal Acetate
Interferes With Actin Remodeling
Induced by 17β-Estradiol and
Progesterone in Human Endometrial
Stromal Cells.
Front. Endocrinol. 9:350.
doi: 10.3389/fendo.2018.00350
Ulipristal Acetate Interferes With
Actin Remodeling Induced by
17β-Estradiol and Progesterone in
Human Endometrial Stromal Cells
Jorge E. Shortrede 1†, Maria M. Montt-Guevara 1†, Gisela Pennacchio 2, Michele Finiguerra 1,
Andrea Giannini 1, Alessandro D. Genazzani 3 and Tommaso Simoncini 1*
1Molecular and Cellular Gynecological Endocrinology Laboratory, Department of Clinical and Experimental Medicine,
University of Pisa, Pisa, Italy, 2 Institute of Experimental Medicine and Biology of Cuyo, Technology and Scientific Center
(CCT)-National Research Council of Argentina, Mendoza, Argentina, 3Department of Obstetrics and Gynecology, Center for
Gynecological Endocrinology, University of Modena and Reggio Emilia, Modena, Italy
Ulipristal acetate (UPA) is a selective progesterone receptor modulator (SPRM) used
for emergency contraception and for the medical management of symptomatic uterine
fibroids (UF). Treatment with UPA turns in amenorrhea and UF volume reduction.
Treatment with UPA is associated with the frequent development of benign, transitory
endometrial changes known as SPRM-associated endometrial changes (PAECs). Why
PAECs develop and their biological or cellular basis is unknown. Sex steroids, including
estrogen and progesterone, are established modulators of the actin cytoskeleton in
various cells, including endometrial cells. This explains several morphological and
functional changes in endometrial cells. We thus hypothesized that UPA may alter the
appearance of the endometrium by interfering with the actions of 17β-estradiol (E2)
or progesterone (P4) on actin dynamics. We isolated and cultured human endometrial
stromal cells (ESC) from endometrial biopsies from healthy fertile women. Treatment
with E2 or P4 stimulated visible actin rearrangements with actin remodeling toward the
membrane. Activation through phosphorylation of the actin regulatory proteins, Moesin,
and focal adhesion kinase (FAK), hacked actin remodeling induced by E2 and P4.
Membrane re-localization of Paxillin and Vinculin were also induced by E2 and P4,
showing the formation of focal adhesion complexes. All these E2 and P4 actions were
inhibited by co-treatment with UPA, which was otherwise inactive if given alone. The
cytoskeletal changes induced by E2 and P4 turned into increased motility of ESC, and
UPA again blocked the actions E2 and P4. In conclusion, we find that UPA interferes with
the cytoskeletal actions of E2 and P4 in ESC. This finding helps understanding the mode
of actions of SPRMs in the endometrium and may be relevant for other potential clinical
applications of UPA.
Keywords: Ulipristal acetate (UPA), endometrial stromal cells (ESC), progesterone (P4), 17β-estradiol (E2), actin
remodeling
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INTRODUCTION
Progesterone receptor (PR) modulators are under
clinical development to treat conditions such as breast cancer,
endometriosis, dysfunctional uterine bleeding, and uterine
fibroids (UF) (1, 2). Since 2012, Ulipristal acetate (UPA) has been
approved in Europe for treatment of UF (3, 4). Ulipristal acetate
is a 19-norprogesterone derivative that inhibits proliferation
and stimulates apoptosis of leiomyoma cells without affecting
normal myometrial cells (3). Its administration is associated with
development of a rapid and stable amenorrhea, which can be in
part explained by interference with the hypothalamus-pituitary-
ovarian axis. Currently, UPA has two major indications in
several countries: emergency contraception (4, 5) and treatment
of symptomatic fibroids (6–8).
Prospective, placebo-controlled, Phase III clinical trials using
UPA in the management of UF (PEARL I, II, III, and IV) have
proved the efficacy and safety of UPA (9). It has been observed
that the use of UPA is associated with endometrial modifications,
known as selective progesterone receptor modulator (SPRM)—
associated endometrial changes (PAEC) (10, 11). PAECs are
benign and reversible with the interruption of the therapy (9).
Nevertheless, the significance of those changes nor the biological
basis are unknown.
Endometrial remodeling is the term used to indicate the set of
cellular processes that dynamically happen during the menstrual
cycle, pregnancy, or in the development of endometrial disorders
(12, 13). These biological phenomena are identified with dynamic
changes in cell architecture and the progressive modifications
of the cell-cell and cell-matrix interactions that determine the
macroscopic endometrial changes (14). One of the processes
related with such phenomena is the ability of cells to remodel
their actin cytoskeleton. Modifications of actin fibers architecture
drives cell membrane reshaping and movement (15, 16). The
major proteins involved in the regulation of focal adhesion
complex formation and actin polymerization/stabilization are
Focal Adhesion kinase (FAK), Paxillin (a scaffolding protein
associated to focal adhesions), and Membrane-Organizing
Extension Spike protein (Moesin).
The aim of the present study was to establish whether
UPA affects the morphology of human ESC with special
attention on how UPA acts on actin cytoskeleton rearrangement,
FAK/Paxillin/Moesin activation and cell migration. To this
extent, we studied the effects of UPA alone or, in the presence
of progesterone or 17β-estradiol.
MATERIALS AND METHODS
Endometrial Cell Sampling
Endometrial samples were obtained from eight women
undergoing diagnostic operative hysteroscopy procedures. All
samples were collected during the follicular phase, based on
the last menstrual period and histological examination of the
samples, between December 2015 and June 2016. All women
were under 45 years with regular menstrual cycles for the past
12 months. Women who underwent endocrine treatments (oral
contraceptives, progestins, GnRH analogues or antagonists) in
the last 3 months or with endometriosis or endometrial cancer
were excluded from the study.
This study was carried out in accordance with the
recommendations of the Good Clinical Practice (ICH/GCP),
Ministerial Decree of 1997. The protocol was approved by the
Regional Ethics Committee for Clinical Trials, North West Wide
Area. All subjects gave written informed consent in accordance
with the Declaration of Helsinki.
Cell Preparation, Culture, and
Characterization of Human Endometrial
Cells
Cell Preparation and Culture
After tissue collection, samples were rapidly immersed in phenol-
red free Dulbecco’s minimal essential medium (DMEM, Gibco,
USA) with 10% FBS (Gibco, USA) plus antibiotic-antimycotic
(ATB, Gibco, USA), and immediately processed for endometrial
cell isolation (17, 18). Under a laminar flow sterile hood, biopsy
samples were mechanically chopped into 1–2 mm3 and washed
with fresh medium to remove blood and mucosa. Then, the
slices were incubated with 10ml of pre-warmed 0.2% type
II collagenase (Sigma-Aldrich, USA) for 60min at 37◦C in a
shaking rotor machine. Following digestion, cell clumps were
mechanically dispersed by aspiration through a Pasteur pipette.
After 10min of differential sedimentation at single gravity, ESC
were separated from large clumps of epithelium. The top 8ml of
medium, containing predominantly stromal cells, were collected
and centrifuged (200 g for 5min). The stromal-enriched fraction
was washed three times with fresh medium. Lastly, ESC were
allowed to adhere selectively to 25 cm2 flask for 15min in phenol-
red free DMEM-F12 (Gibco, USA) supplemented with 10% FBS
and ATB. Afterward, non-attached endometrial epithelial cells
(EEC) were removed and a purified stromal preparation was
obtained. Endometrial stromal cells (ESC) were cultured to sub-
confluence in DMEM-F12 with 10% FBS and ATB and were used
between passages 3 and 10.
Cell Treatments
Before each experiment, medium was replaced for 48 h with
medium containing charcoal stripped-FBS (CS-FBS, which
is steroid-deprived FBS, Lonza, Switzerland), or medium
without FBS, when experiments were conducted to study non-
transcriptional effects. When an inhibitor was used, the active
treatments were added 1 h later. Control cells always received
the same amount of ethanol (solvent for UPA/P4/E2 0.01% final
concentration).
Ulipristal acetate (10−9 to 10−7 M) was kindly provided by
Gedeon Richter, UK. Progesterone (P4, 10−9 to 10−7 M), 17β-
estradiol (E2, 10−9 to 10−7 M), the PR Antagonist Mifepristone
(MIF, 10−5 M), and the Estrogen Receptor (ER) Antagonist
Fulvestrant (ICI 182,780, 10−6 M) were purchased from Sigma-
Aldrich, USA.
Cell Characterization
As previously described, we managed to obtained ESC and
EEC cells in different flasks. In contrast to EEC, ESC appeared
flattened and elongated with a fibroblast-like shape under phase
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contrast microscopy (Figures 1A,B). To corroborate the purity
of cell cultures, we performed western blot of stromal and
epithelial whole cells lysate against cytokeratin 19 and Vimentin.
As expected, stromal cells were Vimentin (+), Cytokeratin (–),
and the epithelial cells were Vimentin low, Cytokeratin (+)
(Figure 1C). In addition, we evaluate the expression of estrogen
(ER) and PR with the purpose to be able to use ESC for the study.
EEC and ESC express both hormone receptors (Figure 1C).
Cell Migration Assays
Wemeasure the collective cell migration with twomethodologies
scratch and wound healing assays. The First one, measure the
migration distance from the scratch of one group of cells,
which is associated with the lateral line model. The second
one, measure the closure of the area of the wound or scratch
and this one is related with the sheet migration model. These
correlated methodologies are not equivalents and both have
different strengths and weaknesses (19).
Scratch Cell Migration Assay
Scratch Cell Migration Assay was performed with a plastic
razor scrape as previously described Montt-Guevara et al.
(20). Briefly, a razor blade was pressed trough the confluent
ESC monolayer to mark the starting line and cells were swept
away on one side of the line. Cells were washed and further
medium containing CS-FBS and cytosine β-D-arabinofuranoside
hydrochloride (Ara-C, Sigma-Aldrich, USA, 10µM) were added
to prevent cell proliferation. Ara-C is a selective inhibitor of
DNA synthesis that does not inhibit RNA synthesis. After
1 h the active treatments were added (T0). Fresh medium
containing the active treatments were replaced every 24 h
and the cultivation was continued for 48 h (T48). Cells
were photographed in five random fields per condition with
Olympus BX41 microscope, DP70 Olympus digital camera.
Cell migration distance covered by the cells between T0
and T48 was measured using NIH ImageJ 1.51q software
(NIH, USA) in three different areas of each photograph. Cell
proliferation in presence of Ara-C was checked in preliminary
experiments by MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-
carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium,
Abcam, England) (Supplementary Figure 1). The Proliferation
Index (PI) was calculated as follows: [ESC treated (O.D.) at time
X/ESC treated (O.D.) at time 0].
Wound Healing Assay
Wound Healing Assay was tested with culture-insert two well
(Ibidi, Germany). Briefly, 20,000 endometrial cells were seeded
with DMEM-F12 containing CS-FBS in both wells. After 48 h,
ESC were washed two times with PBS and incubated with Ara-
C. One hour later all culture-inserts were removed, creating a
cell-free gap of ∼500µm, and culture medium with the active
treatments were added (T0). Migration was monitored for 24 h
(T24). To determine wound closure area, images were taken by
phase contrast microscopy (Olympus) at time 0 and 24 h. The
gap area at T0 and T24 were measured by NIH ImageJ software
performing the following operations: a background subtraction
operation and then using the hand detection command we
outlined the leading cell path and finally measure area. Coverage
areas were calculated as [(Area T0 – Area T24)/Area T0] and
expressed relative to control cell at T24.
Scratch and wound healing assays measure the same
phenomena: collective cell migration. However, the first one,
measure the migration distance from the scratch of one group
of cells, and that is related with the Lateral line model. The other,
measure the closure of the area of the wound or scratch and that
is related with sheet migration model. These methodologies are
not equivalents but correlated and both have different strengths
and weaknesses.
Immunoblottings
After treatments, cells were lysed in buffer Tris-HCl 50mM, pH
7.4, 1mM EDTA, 1% IGEPAL, proteases inhibitor cocktail PIC
FIGURE 1 | Isolation and characterization of human endometrial cells. Cells were obtained from endometrial biopsies and cultured in DMEM-F12 supplemented with
10% FBS. (A) Phase contrast microscopy of Endometrial Stromal Cells (ESC), cells appeared flattened and elongated with a fibroblast-like shape. Photo taken 4 day
after plating (20X). (B) Phase contrast microscopy of EEC cells appeared cuboidal. Photo was taken 4 days after plating. (C) Representative western-blot blot of
Vimentin (VMT), Cytokeratin 19 (KRT-19), Estrogen Receptor alpha (ERα), Progesterone Receptor (PR), and GAPDH. ESC were VMT/ERα/PR positive. EEC were
KRT-19/ERα/PR positive. GAPDH was used as loading control.
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(Sigma-Aldrich, USA), and phosphatase inhibitor cocktail PHIC-
3 (Sigma-Aldrich, USA). Protein concentration was quantified
using BCA method (Thermo Fisher Scientific, USA). Cells
lysates were resolved by SDS-PAGE as previously described (21).
Antibodies against pT558-Moesin (sc-12895), pY397-FAK (sc-
81493), PR (sc-539), Vimentin (sc-66002), ER-alpha (sc-8005),
and GAPDH (sc-59540), as loading control were all purchased
from Santa Cruz Biotechnology, USA; Cytokeratin 19 (KRT-
19, MA5-15884, Thermo Fisher Scientific, USA). Primary and
secondary antibodies were incubated with standard technique.
Immunodetection was visualized by chemiluminescence and
digitalized with Quantity One software (BioRad, USA). Optical
densitometry (OD) analysis of the bands was performed using
the NIH ImageJ software. OD values were expressed as the ratio
of each band vs. their respective loading control.
Immunofluorescence
ESC were grown on coverslips and exposed to different
treatments. ESC were fixed in paraformaldehyde 4%, for 20min
and then incubated with quenching solution (50mM NH4Cl in
PBS) for 20min. Permeabilization and blocking were performed
with 3% bovine serum albumin in PBS/ 0.1% Triton X-100 for
30min. Cells were incubated with primary antibodies against
pTyr118Paxillin (sc-365020, Santa Cruz Biotechnology, USA)
and Vinculin (CP74, Calbiochem, USA) over-night at 4◦C and
Alexa 488 anti-mouse (A11029, Invitrogen, USA) was used as
secondary antibody. In addition, cells were incubated 45min
with Texas Red-X Phalloidin (T7471, Invitrogen, USA) for F-
actin. Nuclei were stained with 4′-6-diamidino-2-phenylindole
(DAPI, D9542, Sigma-Aldrich, USA) and mounted with Ibidi
mounting medium (Ibidi, Germany). Immunofluorescence was
visualized using an Olympus BX41 microscope and recorded
with a DP70 Olympus digital camera.
The quantitative analysis of the remodeling and thickness
of actin fibers was performed on 20 cells per experimental
condition, by using the NIH ImageJ software in two different
ways. The first one involved two separate measures in each cell of
10µm distance encompassing extracellular space, full thickness
of the membrane and intracellular. The program provides a
graph and the mean fluorescence intensity as pixel gray value
of the areas identified as membrane or the cytoplasm. The
membrane/cytoplasm ratio (M/C) was calculated. For the second
one, we performed a background subtraction operation, and then
using the hand detection command we selected the outer surface
of the cell membrane and measured the whole cell RawIntDen (is
the sum of the values of the pixels in the selection). Subsequently,
we selected the inner surface of the cell membrane and measured
the cytoplasmRawIntDen. After that, we calculated theM/C ratio
as [(whole cell RawIntDen – cytoplasm RawIntDen)/cytoplasm
RawIntDen].
Statistical Analysis
Each biological experiment was carried out at least three times
on independent replicates with comparable results. Data were
analyzed using GraphPad Prism 7 software (GraphPad Prims,
USA) employing one-way ANOVA followed by Tukey’s multiple
comparisons test. Results are expressed as mean ± SEM.
Differences at p< 0.05 were considered significant.
RESULTS
UPA Does Not Trigger Moesin and FAK
Phosphorylation in ESC, but Modulates the
Effects of E2 and P4
To evaluate how UPA may affect cytoplasmic alterations
in ESC, we checked if UPA might interfere with
activation/phosphorylation of Moesin (T558) and FAK
(Y397), two major proteins that are responsible for actin
re-shaping.
ESC were treated with increasing concentration of E2, P4
and UPA (10−9 to 10−7 M) for 20min. As expected, E2 and
P4 induced a significant increase of T558Moesin and Y397FAK
phosphorylation. On the contrary, no significant difference was
observed in cells treated with UPA (Figures 2A,B).
Based on the previous results, we selected the following
concentrations for successive experiments: E2 10−9, P4
10−8, UPA 10−8 M. ESC treated with E2+P4 displayed
a rapid T558Moesin phosphorylation compared to
control, but no synergistic action was seen. When ESC
were treated with E2+UPA or P4+UPA, T558Moesin
phosphorylation did not differ from the control. In
addition, ESC treated with P4+UPA revealed a significant
decrease of T558Moesin phosphorylation compared to P4
(Figure 2C).
When we analyzed the phosphorylation of Y397FAK, we found
that ESC treated with E2+P4 displayed a significant Y397FAK
phosphorylation compared to control and no synergistic action
was seen. Similarly, when ESC were treated with E2+UPA or
P4+UPA we observed no induction of Y397FAK phosphorylation
compared to control. Moreover, UPA significantly decreased
Y397FAK phosphorylation induced by P4 and E2 (Figure 2D).
UPA Does Not Activate Actin Cytoskeleton
Rearrangement in Endometrial Stromal
Cells, but Modulates the Effects of E2 and
P4
In order to characterize UPA cytoskeletal changes on normal
ESC, we first studied whether it could modified the arrangement
of actin filaments. We performed immunofluorescence studies
to refine the localization of actin filaments with Texas Red-X
Phalloidin.
Cells were treated with E2 10−9, P4 10−8, UPA 10−8, ICI 10−6
M (Fulvestrant, an ER inhibitor), MIF 10−5 M (Mifepristone, a
progesterone receptor inhibitor), and the combinations (E2+P4,
E2+UPA, P4+UPA, E2+ICI, and P4+MIF) for 30min to
observe actin cytoskeleton rearrangement.
Control cells displayed mainly longitudinally arranged actin
fibers with regular cell borders. In addition, non-substantial
changes were observed in cells treated with E2+ICI, P4+MIF,
UPA, E2+UPA, or P4+UPA. However, when cells were treated
with E2 and P4 or the combination (E2+P4), we observed actin
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FIGURE 2 | UPA inhibits Moesin and FAK activation induced by E2 and P4. ESC treated for 20min with increasing concentration of E2, P4, UPA (A,B) and the
combinations: E2+P4, E2+UPA, and P4+UPA (C,D). Lower panels, show representative blot of pT558Moesin, pY397FAK, and GAPDH. Upper panels, show the
quantitative analysis of OD of western blot represented as mean ± SEM of pT558Moesin/GAPDH and pY397FAK/GAPDH ratio relative to control. Four independent
experiments were performed. The data were analyzed statistically by one-way ANOVA, followed by Tukey’s multiple comparison test (*p < 0.05, **p < 0.01,
***p < 0.001 vs. control); (#p < 0.05 vs. E2 10−9 M); (◦◦◦p < 0.001 vs. P4 10−8 M).
filaments reorganization in the proximity of the cell membrane
(Figures 3A,B).
We analyzed the membrane/cytoplasm (M/C) ratio by two
different methods with comparable results. As expected, cells
treated with E2, P4 and the combination, showed a significant
increase on M/C ratio compared to control. The effects of E2
and P4 were counteracted by their specific inhibitors. UPA
counteracted the actions of E2 and P4 on actin remodeling. The
inhibition associate with UPA was analogous to that induced by
ICI or MIF (Figures 3C,D).
P4 and E2, but Not UPA, Trigger Vinculin
and py118Paxillin Localization at the Cell
Membrane
It is documented that focal adhesion complexes formation is
associated to actin rearrangement, as an early step in cell
migration (22–24). For this reason, we chose to study two
proteins that participate in focal adhesion complexes, Vinculin
and Paxillin. The first one is involved in the linkage of integrins,
matrix adhesion molecules, to the actin cytoskeleton. The second
one is a scaffolding protein activated by phosphorylation on
Y118 residue; it serves as a platform for the recruitment
of several regulatory proteins that modulate the assembly
and disassembly of the focal adhesion complexes, linked to
actin rearrangement. We investigated whether UPA could
modulate focal adhesion complexes formation in the presence of
E2 or P4.
ESC were treated with E2 10−9, P4 10−8, UPA 10−8, ICI
10−6, and MIF 10−5 M and their combinations for 48 h. Then
cells were fixed and immunofluorescence was performed. Images
were taken with a 100x objective magnification. All images
were subjected to the same parameters values for background
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FIGURE 3 | UPA inhibits actin rearrangement induced by E2 and P4. ESC treated for 30min with E2, P4, UPA, ICI, MIF and the combinations. Actin fibers were
stained with Texas Red-X phalloidin (red), and nuclei were counterstained with DAPI (blue). (A) Representative immunofluorescence images and descriptive plot-profile
of fluorescence intensity measured as gray value. (B) Representative immunofluorescence images with the selected outer and inner surface of the cell membrane.
(C,D) Quantitative analysis graph of pixel intensity represented as mean ± SEM of membrane/cytoplasm ratio (M/C ratio) relative to control. Three independent
experiments were performed. The data were analyzed statistically by one-way ANOVA, followed by Tukey’s multiple comparison test (*p < 0.05, **p < 0.01,
***p < 0.001 vs. control); (#p < 0.05, ##p < 0.01 vs. E2 10−9 M); (◦p < 0.05, ◦◦p < 0.01 ◦◦◦p < 0.001 vs. P4 10−8 M).
subtraction with the background correction plugin of imageJ
software.
We observed that E2, P4, and E2+P4 treatments stimulated
the localization of Vinculin and Y118Paxillin phosphorylation as
discrete punctuated pattern (typical of focal adhesion complexes)
at the cell membrane (Figures 4A,B, yellow arrows). On the
contrary, cells treated with UPA, ICI, MIF, and combinations
like E2+UPA, P4+UPA, E2+ICI, and P4+MIF did not show the
recruitment of Vinculin or Y118Paxillin phosphorylation to the
plasma membrane (Figures 4A,B).
UPA Does Not Stimulate ESC Migration,
but Modulates the Effects of E2 and P4
To assess if UPA cytoskeletal changes could affect cell motility of
human ESC we performed cell migration assays.
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FIGURE 4 | UPA inhibits the formation of focal adhesion complexes induced by E2 and P4. Representative merge immunofluorescence images from ESC treated for
48 h with UPA, P4, E2, ICI, MIF, and the combinations. Cells were fixed and incubated with (A) anti-Vinculin or (B) anti-pY118Paxillin linked to Alexa Fluor 488 (green),
F-Actin was stained with Texas Red-X phalloidin (red), and nuclei with DAPI (blue). Yellow arrows indicate Vinculin and pY118Paxillin localization as discrete punctuated
pattern, typical of focal adhesion points.
ESC were treated with increasing concentration of E2, P4, and
UPA (10−9 to 10−7 M) and combinations for 48 h. As expected,
cells treated with P4 and E2 significantly increased cell migration
from the lowest dose used. However, UPA treatment did not
promote cell migration (Figure 5A).
For the first combination, E2+P4, we found that E2
(10−9 M) with increasing concentration of P4 (10−9 to
10−7 M) significantly stimulated cell migration compared to
control. Moreover, cells treated with E2+P4 10−7 M had
significantly highermigratory effect compared to E2 and P4 alone
(Figure 5B).
For the second combination, E2+UPA, we found that E2
(10−9 M) with increasing concentration of UPA (10−9 to
10−7 M) only E2+UPA 10−9 M significantly increased cell
migration compared to the control. However, UPA (10−8 to
10−7 M) counteracted in a concentration-dependent manner cell
migration induced by E2. Finally, UPA significantly antagonized
cell migration induced by P4 (Figure 5B).
To corroborate the results obtained in the previous
experiments, we decided to evaluate cell migration with
wound healing assay micro-inserts system. Images were taken
at 0 and 24 h (Supplementary Figure 2A). We confirmed that
E2, P4, and E2+P4 significantly stimulate wound closure. Once
more, UPA did not show significant differences compared to
control. We also observed a significant decrease on wound
closure when we compared E2+ICI vs. E2 and P4+MIF vs. P4.
Similarly, when cells were treated with E2+UPA and P4+UPA,
a significant reduction of cell migration compared to E2 and P4
was found (Supplementary Figure 2B).
DISCUSSION
Human endometrium is the inner mucosa of the uterus,
which undergoes cycles of regeneration (cell proliferation and
migration), differentiation, and shedding during a woman’s
reproductive life. Moreover, the endometrium is one of
the most responsive tissues to sex steroid hormones like
progesterone (P4) and 17β-estradiol (E2) (25). Reciprocal
paracrine signaling driven by fluctuating sex steroid hormones
determines the stromal-epithelial cell functional expression
patterns, proliferation state and rate of apoptosis (26). These
dynamic changes on the endometrium are related to a set
of cellular processes that happens during menstrual cycle,
pregnancy, or the development of endometrial disorders (13). For
these reasons, the isolation of ESC from healthy patients is an
interesting in vitromodel to study the effects of the SPRM, UPA.
The histopathological endometrial changes found in patients
treated with UPA have been partially characterized (2, 9, 27,
28). These reversible endometrial modifications, have been
described as benign, non-proliferative histologic features of the
endometrium, and named Progesterone Receptor Modulator-
Associated Endometrial Changes (PAECs) (10, 11). The cellular
basis for such processes is unclear, but may well be based on
altered cell cytoskeleton dynamics.
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FIGURE 5 | UPA inhibits ESC motility induced by E2 and P4. Cells scratch migration assays were performed with a razor blade pressed trough the confluent ESC
monolayer to mark the starting line, then cells were swept away on one side of that line. ESC were treated with increasing concentration of UPA, P4, E2, and the
combinations for 48 h. (A) Representative ESC migration images taken at 0 and 48 h. The short white lines represent the average distance of three measurements in
the same image. (B) Quantitative analysis of cell migration represented as the mean ± SEM migration distance from the starting line relative to the control. Five
independent experiments were performed. The data were analyzed statistically by one-way ANOVA, followed by Tukey’s multiple comparison test (***p < 0.001 vs.
control) (###p < 0.001 vs. E2 10−9 M) (⊗p < 0.05 vs. P4 10−9 M) (◦◦◦p < 0.001 vs. P4 10−8 M) (•p < 0.05, •••p < 0.001 vs. P4 10−7 M).
In this study, we present evidence that UPA modulates
E2 and P4 effects on actin filaments rearrangement and on
phosphorylation status of FAK and Moesin. In addition, we
demonstrate that UPA does not promote the recruitment of
vinculin and pY118Paxillin to the leading edge of the plasma
membrane as a discrete punctuated pattern, typical of focal
adhesion points. These findings may suggest that UPA alters cell
morphology by interfering with the cytoskeletal action of E2 and
P4 in the endometrium.
In the recent past, the role of FAK, Paxillin, and Moesin
in relationship with sex steroids in the biology of normal and
cancer cells has been the subject of extensive investigation (29–
32). Membrane-Organizing Extension Spike protein (Moesin)
functions as a cross-linker between plasma membrane and the
actin cytoskeleton. Focal Adhesion Kinase (FAK) is a non-
receptor tyrosine kinase that regulates the formation of focal
adhesion complexes, which provide anchoring sites for cell
attachment to the extracellular matrix. Our group and others
have reported diverse possible mechanistic explanations on
how E2 and P4 regulate these biological processes (30, 31,
33–36). Estrogens receptors (ER) and PR recruit G-alpha-13
and promote the activation of the Src/FAK/Paxillin complex
and its interaction with Vinculin, leading to N-WASP/ARP2/3
complex activation. On the other side, ER, and PR activate the
G-alpha-13/Src/Rho-A/Rock-2/Moesin cascade. Both pathways
promote cytoskeletal remodeling that leads to cell migration
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and regulate different cellular functions in endometrial cells
(30, 37–39).
A recent observational study conducted by Whitaker et al.,
in women developing PAEC during treatment with UPA, shows
that UPA alters the expression pattern of both PR and androgen
receptors, decreasing endometrial cell proliferation rate (40).
From in vivo, in vitro, and pre-clinical studies, we now know that
UPA binds with high affinity to PR (41, 42), and in a weakmanner
to ER (43). This could be an explanation for the modulation
of cell migration and actin filaments reorganization by UPA in
presence of E2 and P4. Based on our results, PAECs could be
related to the interference of UPA on cytoskeleton rearrangement
modulated by E2 and P4 on ESC. Consequently, this would
reinforce the idea that PAECs are not related to proliferative
actions. However, why not all subjects develop PAECs upon
expose to UPA is uncertain and the impact of this phenomenon
on bleeding control is unknown.
Understanding the molecular basis of UPA actions on the
endometrium may turn out to be relevant for several potential
clinical applications, including endometriosis, adenomyosis, or
estrogen/progesterone sensitive cancers. Studies suggest that
UPA is a promising endocrine therapy for hormone-sensitive
tumors like breast or endometrial cancer. Particularly, Esber
et al., found anti-proliferative and pro-apoptotic effects in
patient-derived breast cancer xenografts in nude mice exposed to
UPA (44, 45). Other groups observed that UPA is able to reverse
E2 and P4 actions by decreasing breast cell proliferation and
hormone receptor expression on BRCA1-mutated breast tissue
xenografted in mice; suggesting that a subset of women with
BRCA1 mutations could be candidates for UPA treatment as a
preventive breast cancer strategy (46). These studies are therefore
the proof-of-concept that the selective antagonism with PR of
UPA could be used in other clinical settings.
In conclusion, we demonstrate that UPA interferes with
E2 and P4 actions in ESC by decreasing actin cytoskeleton
rearrangement, focal adhesion formation, and reducing FAK and
Moesin phosphorylation/activation. Moreover, this corresponds
to the inhibition of cell motility. These findings add to our current
understanding of the bio-molecular mechanism of actions of
UPA and SPRMs on endometrial cells and highlight how
cytoskeletal actions of UPA could be of interest to its clinical
actions.
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Supplementary Figure 1 | Effects of 10µM Ara-C on ESC proliferation. ESC
were treated with E2 10−9, P4 10−8, UPA 10−8, ICI 10−6 M. and MIF 10−5 M
and the combinations for 72 h. Proliferation was measured by MTS assay every
24 h. Results are shown as the mean ± SEM of proliferation indexes (PI) of three
experiments performed in triplicate. Data were analyzed statistically by one-way
ANOVA. Cells incubated with Ara-C did not have significant effect on PI.
Supplementary Figure 2 | UPA modulates the effects of E2 and P4 on ESC
motility, similar to ICI and MIF. Wound Healing micro-inserts assay, was tested with
culture–insert 2 well. ESC were treated with UPA, P4, E2, ICI, MIF, and the
combinations for 24 h. (A) Representative phase contrast microscopy image taken
at 0 and 24 h. (B) Quantitative analysis graph of cell migration represented as
mean ± SEM of the percentage of wound closure area relative to the control.
Three independent experiments were performed. The data were analyzed
statistically by one-way ANOVA, followed by Tukey’s multiple comparison test
(∗∗p < 0.01, ∗∗∗p < 0.001 vs. control) (##p < 0.01 vs. E2 10−9 M) (◦p < 0.05,
◦◦p < 0.01 vs. P4 10−8 M).
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